Hikal Limited · NSE:HIKAL
Hikal — Q3 FY22 Earnings Presentation
26 slides from Hikal's earnings presentation
Slide 1: Results Presentation – Q3 FY22
Results Presentation – Q3 FY22
Slide 2: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Hikal Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and
Slide 3: Executive Chairman's Message
Executive Chairman’s Message “Hikal has recorded a resilient performance in Q3 as we continued the growth trajectory that the company has established over the past few quarters. Despite the hurdles presented by global supply chain challenges combined with increasing raw material as well as utility p
Slide 4: Quarterly Financials Highlights
Quarterly Financials Highlights
Slide 5: Financial Highlights – Q3 FY22
Financial Highlights – Q3 FY22 Revenue – Q3 FY22 EBITDA – Q3 FY22 EBITDA Margin – Q3 FY22 Rs. 515 Crore Rs. 93 Crore 18.1% YoY QoQ YoY QoQ YoY QoQ 11% 10% 2% 2% -166 bps -132 bps PAT – Q3 FY22 EPS – Q3 FY22 Rs. 45 Crore Rs 3.67 YoY QoQ YoY QoQ 12% 3% 12% 3% © Hikal Limited
Slide 6: Quarterly Performance Highlights
Quarterly Performance Highlights Revenue +11% Performance Highlights 515 463 469 • Revenue recorded an increase of 11% YoY • Change in product mix and increase demand of key products • Strong performance in Pharma own products and Crop Protection CDMO segments Q3FY21 Q2FY22 Q3FY22 • EBITDA increased
Slide 7: Quarterly Performance Highlights – Pharmaceuticals
Quarterly Performance Highlights – Pharmaceuticals Revenue 0% Pharmaceuticals - Performance Highlights 269 280 268 • Recorded flat revenue at Rs. 268 Crore as compared to Q3 FY21 • Stable sales corresponding with change in product mix • EBIT stood at Rs 36 Crore, de-growth of 25% YoY • Product mix c
Slide 8: Quarterly Performance Highlights – Crop Protection
Quarterly Performance Highlights – Crop Protection Revenue +27% Crop Protection - Performance Highlights 246 • Revenue stood at Rs. 246 Crores, recorded an increase of 27% YoY 194 190 • Increased sales volume of CDMO products • Favorable price increases for certain products • EBIT of Rs 38 Crore, gr
Slide 9: Quarterly Financial Highlights
Quarterly Financial Highlights Consolidated Revenue Consolidated EBITDA Consolidated PAT 11% 2% 12% 532 109 51 51 515 463 469 96 44 45 457 91 91 93 40 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Rs. Crore © Hikal Limited
Slide 10: Quarterly Segmental Highlights
Quarterly Segmental Highlights Pharmaceuticals Revenue Crop Protection Revenue -0.3% 27% 298 269 274 280 268 246 235 194 183 190 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Pharmaceuticals EBIT Crop Protection EBIT -25% 22% 51 48 48 48 38 37 36 34 31 32 Q3FY21 Q4FY21 Q1FY22
Slide 11: Consolidated Profit & Loss – Q3 FY22
Consolidated Profit & Loss – Q3 FY22 Particulars (Rs. Crore) Q3 FY22 Q3 FY21 Y-o-Y Q2 FY22 Q-o-Q Net Sales 515 463 11% 469 10% Expenditure 422 372 378 EBITDA 93 91 2% 91 2% Margin 18.1% 19.7% 19.4% Other Income 1 1 1 Depreciation 25 22 24 Finance Costs 7 8 8 PBT 62 62 -0.6% 60 3% Tax 17 22 16 Net Pr
Slide 12: Nine-Months Financials Highlights
Nine-Months Financials Highlights
Slide 13: Financial Highlights – Nine-Months
Financial Highlights – Nine-Months Revenue – 9M FY22 EBITDA – 9M FY22 EBITDA Margin – 9M FY22 Rs. 1,440 Crore Rs. 280 Crore 19.4% YoY YoY YoY 21% 31% 142 bps PAT – 9M FY22 EPS – 9M FY22 Rs. 140 Crore Rs 11.33 YoY YoY 70% 70% © Hikal Limited
Slide 14: Nine-Months Performance Highlights
Nine-Months Performance Highlights Revenue EBITDA PAT +21% +31% +70% 1,440 280 140 1,188 214 82 9MFY21 9MFY22 9MFY21 9MFY22 9MFY21 9MFY22 Pharmaceuticals Division Crop Protection Division +8% +45% 822 619 762 426 Revenue Revenue 9MFY21 9MFY22 9MFY21 9MFY22 +2% +86% 119 121 104 56 EBIT EBIT Rs. Crore
Slide 15: Sales Break-Up
Sales Break-Up Pharmaceuticals Revenue Break-Up Crop Protection Revenue Break-Up CDMO CDMO Own products Own products 47.8% 42.9% 63.9% 81.1% 52.2% 57.1% 36.1% 18.9% 9MFY21 9MFY22 9MFY21 9MFY22 © Hikal Limited
Slide 16: Ratio Analysis
Ratio Analysis ROE ROCE 19.0% 18.5% 15.2% 14.5% 16.1% 15.2% 12.0% 12.8% 11.3% 10.7% 12.5% 11.1% FY17 FY18 FY19 FY20 FY21 9MFY22* FY17 FY18 FY19 FY20 FY21 9MFY22* Net Debt / Equity Net Debt / EBITDA 0.94 0.91 2.9 0.83 2.5 0.71 2.1 2.1 0.61 0.57 1.8 1.6 FY17 FY18 FY19 FY20 FY21 9MFY22* FY17 FY18 FY19
Slide 17: Annual Financials Highlights
Annual Financials Highlights
Slide 18: Financial Highlights - Annual
Financial Highlights - Annual Revenue – FY21 EBITDA – FY21 EBITDA Margin – FY21 Rs. 1,720 Crore Rs. 323 Crore 18.8% FY17-21 FY17-21 YoY YoY YoY CAGR CAGR 14% 18% 65 bps 14% 13% PAT – FY21 EPS – FY21 Rs. 133 Crore Rs 10.80 FY17-21 FY17-21 YoY YoY CAGR CAGR 58% 58% 19% 19% © Hikal Limited
Slide 19: Annual Performance Highlights
Annual Performance Highlights Revenue EBITDA PAT +14% +18% +58% 1,720 323 133 1,507 273 84 FY20 FY21 FY20 FY21 FY20 FY21 Pharmaceuticals Division Crop Protection Division +19% +7% 1,060 620 661 887 Revenue Revenue FY20 FY21 FY20 FY21 +33% +4% 170 100 103 128 EBIT EBIT Rs. Crore FY20 FY21 FY20 FY21 ©
Slide 20: Yearly Financial Highlights
Yearly Financial Highlights Consolidated Revenue Consolidated EBITDA Consolidated PAT 14% 13% 19% 1,720 323 133 1,590 298 1,507 273 1,300 242 103 197 84 1,034 77 67 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 Rs. Crore © Hikal Limited
Slide 21: Yearly Segmental Highlights
Yearly Segmental Highlights Pharmaceuticals Revenue Crop Protection Revenue +15% 12% 1,060 651 661 620 939 887 547 753 423 611 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 Pharmaceuticals EBIT Crop Protection EBIT +21% +8% 170 112 100 103 129 128 87 75 99 79 FY17 FY18 FY19 FY20 FY21 FY17 FY18 F
Slide 22: Sales Break-Up
Sales Break-Up Pharmaceuticals Revenue Break-Up Crop Protection Revenue Break-Up CDMO CDMO Own products Own products 41.2% 54.0% 69.0% 76.7% 58.8% 46.0% 31.0% 23.3% FY20 FY21 FY20 FY21 © Hikal Limited
Slide 23: Consolidated Profit & Loss – Full Year
Consolidated Profit & Loss – Full Year Particulars (Rs. Crore) FY21 FY20 Y-o-Y Net Sales 1,720 1,507 14% Expenditure 1,397 1,234 EBITDA 323 273 18% Margin 18.8% 18.1% Other Income 5 4 Depreciation 85 82 Finance Costs 36 52 Exceptional Item - 15 PBT 206 127 63% Tax 73 42 Net Profit 133 84 58% Margin
Slide 24: Annual Dividend Payout
Annual Dividend Payout Dividend Payout 19% 14% 24% 22% 18% 19% 17% 20% 19% 11%* including DDT 11.33 EPS DPS 10.80 8.36 6.85 6.27 5.70 5.18 3.28 3.35 2.05 2.00 0.90 1.00 1.20 1.20 1.20 1.20 1.20 1.00 0.50 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 9M FY22* The above dividend is based on Face Value
Slide 25: Contact Us
Contact Us Company : Investor Relations Advisors : Hikal Limited Strategic Growth Advisors Pvt. Ltd. CIN: L24200MH1988PTC048028 CIN: U74140MH2010PTC204285 Mr. Kuldeep Jain Mr. Jigar Kavaiya +91-9920602034 Kuldeep_jain@hikal.com jigar.kavaiya@sgapl.net www.hikal.com www.sgapl.net © Hikal Limited
Slide 26: HIKAL
HIKAL